Loading...
Market
What will be the primary indication for Mounjaro sales in HK by mid-2025?
2
Resolution / Starting Odds
Weight Loss • 25%
Type 2 Diabetes • 25%
Both equally • 25%
Other • 25%
Sales reports or market analysis from Eli Lilly or market research firms
Story
Eli Lilly Gets Hong Kong Approval to Launch Mounjaro, First Weight-Loss Drug in China Region
Oct 28, 2024, 01:17 AM
Eli Lilly & Co. is set to launch its blockbuster weight-loss drug Mounjaro in Hong Kong by the end of this year, following approval from the Hong Kong government, Bloomberg News reported. Mounjaro, also known as tirzepatide, is approved for weight management and type 2 diabetes. This launch will make Mounjaro the first weight-loss drug available for sale in the China region, potentially tapping into a significant market across the border. The drug will be available in Kwikpen form.
View original story
Similar markets
Under $50 million • 25%
$50-$100 million • 25%
$100-$150 million • 25%
Over $150 million • 25%
Top 3 • 25%
4th to 6th • 25%
7th to 9th • 25%
10th or lower • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Mounjaro > 60% • 25%
Mounjaro 40-60% • 25%
Ozempic 40-60% • 25%
Ozempic > 60% • 25%
Weight Reduction • 25%
Cardiovascular Benefits • 25%
Diabetes Management • 25%
Other • 25%
Mounjaro leads • 25%
Competitor A leads • 25%
Competitor B leads • 25%
Other drug leads • 25%
Yes • 50%
No • 50%
Achieves blockbuster status in 2025 • 25%
Achieves blockbuster status in 2026 • 25%
Achieves blockbuster status in 2027 • 25%
Does not achieve blockbuster status by end of 2027 • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%